RSV-associated mortality in the ISI-RSV risk groups for 43 patients presenting with RSV infection at the LRTI stage stratified according to antiviral therapy
| . | . | . | Antiviral therapy at LRTI stage . | |||
|---|---|---|---|---|---|---|
| No . | Yes . | |||||
| Risk group . | No. . | Deaths, n (%) . | No. . | Deaths, n (%) . | No. . | Deaths, n (%) . |
| Low | 5 | 0 | 2 | 0 | 3 | 0 |
| Moderate | 26 | 6 (23) | 0 | NA | 26 | 6 (23) |
| High | 12 | 6 (50) | 0 | NA | 12 | 6 (50) |
| . | . | . | Antiviral therapy at LRTI stage . | |||
|---|---|---|---|---|---|---|
| No . | Yes . | |||||
| Risk group . | No. . | Deaths, n (%) . | No. . | Deaths, n (%) . | No. . | Deaths, n (%) . |
| Low | 5 | 0 | 2 | 0 | 3 | 0 |
| Moderate | 26 | 6 (23) | 0 | NA | 26 | 6 (23) |
| High | 12 | 6 (50) | 0 | NA | 12 | 6 (50) |
NA, not applicable.